Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1080/14740338.2021.1867100 http://scihub22266oqcxt.onion/10.1080/14740338.2021.1867100 33393387!ä!33393387 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Expert+Opin+Drug+Saf 2021 ; 20 (6): 651-667 Nephropedia Template TP {{tp|p=33393387|t=2021. Safety of current immune checkpoint inhibitors in non-small cell lung cancer |pdf=|usr=}}{{33393387}} gab.com Text Safety of current immune checkpoint inhibitors in non-small cell lung cancer JO: Expert Opin Drug Saf http://www.kidney.de/pget.php?&tw=1&pmid=33393387 #FOAvip Introduction: Immune checkpoint inhibitors (ICIs) achieved response rates around 20% in advanced non-small cell lung cancer (NSCLC) with 8% of patients becoming long-term survivors. Outcomes have improved with the addition of chemotherapy to immunotherapy or the combination of anti-PD(L)1 with anti-CTLA-4 agents.Areas covered: The incidence of immune-related adverse events (irAEs) in patients with NSCLC treated with ICIs varied across clinical trials and real-life studies. The onset of irAEs was 10 weeks. Toxic deaths from irAEs following anti-PD(L)1 administration resulted mainly from pneumonitis. Some irAEs such as rash and thyroiditis were probably associated with better clinical outcomes, though confounding biases exist. Investigations are on-going to determine ideal biomarkers to predict the occurrence, to screen for and to diagnose irAEs.Expert opinion: Prevention, anticipation, detection, treatment and careful monitoring are the five principles that characterize our management of irAEs. Distinguishing immune-induced pneumonitis from progression, pseudo progression, hyper progression, or other etiologies (COVID-19) can be particularly challenging in lung cancer due to the baseline vulnerable pulmonary function and thus requires caution and teamwork. We treat patients according to institutional and international guidelines and we only rechallenge them with ICIs after resolution of the AE and corticosteroid tapering. Twit Text FOAVip Safety of current immune checkpoint inhibitors in non-small cell lung cancer ????Expert Opin Drug Saf http://www.kidney.de/pget.php?&tw=1&pmid=33393387 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33393387 #FOAvip English Wikipedia <ref>{{Cite pmid|33393387}}</ref> Safety of current immune checkpoint inhibitors in non-small cell lung cancer #MMPMID33393387 Abdayem P; Planchard D Expert Opin Drug Saf 2021[Jun]; 20 (6): 651-667 PMID33393387show ga Introduction: Immune checkpoint inhibitors (ICIs) achieved response rates around 20% in advanced non-small cell lung cancer (NSCLC) with 8% of patients becoming long-term survivors. Outcomes have improved with the addition of chemotherapy to immunotherapy or the combination of anti-PD(L)1 with anti-CTLA-4 agents.Areas covered: The incidence of immune-related adverse events (irAEs) in patients with NSCLC treated with ICIs varied across clinical trials and real-life studies. The onset of irAEs was 10 weeks. Toxic deaths from irAEs following anti-PD(L)1 administration resulted mainly from pneumonitis. Some irAEs such as rash and thyroiditis were probably associated with better clinical outcomes, though confounding biases exist. Investigations are on-going to determine ideal biomarkers to predict the occurrence, to screen for and to diagnose irAEs.Expert opinion: Prevention, anticipation, detection, treatment and careful monitoring are the five principles that characterize our management of irAEs. Distinguishing immune-induced pneumonitis from progression, pseudo progression, hyper progression, or other etiologies (COVID-19) can be particularly challenging in lung cancer due to the baseline vulnerable pulmonary function and thus requires caution and teamwork. We treat patients according to institutional and international guidelines and we only rechallenge them with ICIs after resolution of the AE and corticosteroid tapering. |Adrenal Cortex Hormones/therapeutic use[MESH] |COVID-19/diagnosis[MESH] |Carcinoma, Non-Small-Cell Lung/*drug therapy[MESH] |Diagnosis, Differential[MESH] |Disease Progression[MESH] |Drug-Related Side Effects and Adverse Reactions[MESH] |Exanthema/*chemically induced/drug therapy/immunology[MESH] |Humans[MESH] |Immune Checkpoint Inhibitors/*adverse effects/therapeutic use[MESH] |Lung Neoplasms/*drug therapy[MESH] |Pneumonia/*chemically induced/diagnosis/drug therapy/immunology[MESH] |Practice Guidelines as Topic[MESH] |SARS-CoV-2[MESH]Safety of current immune checkpoint inhibitors in non-small cell lung (epmc).pdf DeepDyve Pubget Overpricing